Chronic Obstructive Pulmonary Disease COPD Clinical Trial
Official title:
A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (AERISTO)
This is a phase IIIb randomised, double-blind, double-dummy, multicentre, parallel group, 24 week study to assess the efficacy and safety of Glycopyrronium/Formoterol Fumarate (GFF) fixed-dose combination 7.2/4.8 μg 2 inhalations twice daily compared to Umeclidinium/Vilanterol (UV) 62.5/25 μg fixed-dose combination 1 inhalation once daily in Patients with moderate to very severe COPD.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02238483 -
A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy
|
Phase 2 | |
Completed |
NCT03131362 -
Realize the Current Situation of COPD Patients in China
|
||
Completed |
NCT01682447 -
Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With COPD
|
N/A | |
Completed |
NCT02645253 -
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men
|
Phase 1 | |
Completed |
NCT02971293 -
Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871
|
Phase 2 |